Average Brokerage Recommendation for Celldex Therapeutics, Inc. (CLDX)

Test tubes with background of chemical structures

Test tubes with background of chemical structures

The last session's volume of 4.10 million shares was higher than its average volume of 1.93 million shares. Dimensional Fund Advisors LP raised its position in shares of Celldex Therapeutics, Inc. The research firm Initiated the stock to Buy. Other firms include Jefferies giving Hold rating on 8-Mar-16.

03/07/2016 - Celldex Therapeutics, Inc. was downgraded to "market perform" by analysts at Leerink Swann.

05/09/2016 - Celldex Therapeutics, Inc. had its "neutral" rating reiterated by analysts at Wedbush. Over the 52-week time span, the stock notched a high price of $5.13 and its minimum price was $2.85. Full-year profit views are for Celldex Therapeutics, Inc.to earn -$1.31 in current year and drop profits by almost 0% over last year's earnings of -$1.31.

The company's stock now has 414.62 Million in market capitalization. They now have a United States dollars 4 price target on the stock. The companys lead drug candidates comprise Rintega (CDX-110), a therapeutic vaccine in Phase III clinical studies for the treatment of glioblastoma patients that express an epidermal growth factor receptor variant III, as well as in Phase II study for the treatment of recurrent glioblastoma; Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate (ADC) in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma; and Varlilumab (CDX-1127), an immune modulating antibody is in Phase I study for the treatment of multiple solid tumors. NASDAQ:CLDX may hit a high of $10. The stock now has an average rating of "Buy" and an average price target of $7.63.

Celldex Therapeutics, Inc. has a 50 day moving average of 3.43 and a 200 day moving average of 3.66.

In the past 6 months, 5 Insider purchases and 1 Insider Sales were made in which 25800 shares were traded as Insider purchases and 25000 shares were exchanged as Insider Sales. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.04.

Top line figures for the fourth quarter rose 4% to $ 1.87 million from $ 1.79 million in the same quarter previous year, where as analysts anticipated $ 1.08 million.

When we look at the recommendation trends, the stock presently has an average brokerage recommendation of 1.6. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock.

The analysts offering 12 month price targets for Celldex Therapeutics, Inc. have a median target of $7, with a high estimate of $10 and a low estimate of $4. FMR LLC now owns 19,327,111 shares of the biopharmaceutical company's stock valued at $68,418,000 after buying an additional 5,555,595 shares in the last quarter. This showed the surprise of 11.8% in the last quarter earnings.

Profitability analysis helps a great deal in making investment decision. Price per earning (ttm) stands at 0.

More analysts at Reuters have a buy or better ratings (5) on the Celldex Therapeutics, Inc. stock than those who have a hold (3) rating while the 12-month target price suggested by the average analysts is $7.5. The most recent short interest data show 15.8% of the company's stock are short sold.

Recommended News

  • Highly-venomous cobra escapes Florida home; residents panic

    Highly-venomous cobra escapes Florida home; residents panic

    Some people here are too scared to be in their own homes, fearing about not knowing where the venomous snake might be hiding. It hasn't been seen since and officials say they aren't sure if it's actually escaped the home.
    Trump's approval rating drops by five points in new poll

    Trump's approval rating drops by five points in new poll

    Less than a week ago, a poll from CNN/ORC showed Melania Trump's approval rating had overtaken her husband's. Nineteen percent of voters say they don't have an opinion of the bill.
    'The Amazing Race' 2017 - Meet the 22 Contestants!

    'The Amazing Race' 2017 - Meet the 22 Contestants!

    OMG! Beauregard and 21 others will take part in a race around the world spanning nine countries and 36,000 miles. Three of the participants , all of whom are competing for the $1 million prize, are from Colorado.
  • 'Beauty and the Beast' stars join James Corden for 'Crosswalk Musical'

    'Beauty and the Beast' stars join James Corden for 'Crosswalk Musical'

    His sexuality is not overplayed, and takes more of a role as character development than as an overarching theme. They step out onto the crosswalk to perform the movie's musical numbers while the traffic light is red.
    Hearing on gag order in Tara Grinstead murder case

    Hearing on gag order in Tara Grinstead murder case

    He added that because the gag order was not against the media itself, it did not violate any constitutional rights. Two weeks ago, Cross ordered investigators, lawyers and possible witnesses not to comment publicly on the case.
    Cannon AFB airmen from Tuesday plane crash in New Mexico identified

    Cannon AFB airmen from Tuesday plane crash in New Mexico identified

    Becker, 33, was originally from Novi, Mich. and worked as a pilot for the 318th Special Operations Squadron at the base. Cannon Air Force Base has identified the three aircrew members who died in a U-28A aircraft crash.
  • Aug man's death ruled a homicide; Investigators looking into dead roommate's vehicle

    Canard was making a left turn onto Hastings Road when a motorcycle going quickly smashed into the side of his vehicle. The auto rolled over after the impact, throwing Canard out.

    Samsung Galaxy Note 8 Rumors Roundup

    The Galaxy Note 8 may not be everyone's sole focus right now, what with the Galaxy S8 gearing up for a release date next month. If you're a Samsung Galaxy Note fan you'll know all about the little Samsung stylus and the fun you can have with it.
    Solar company Sungevity files for bankruptcy, agrees to sell assets

    Solar company Sungevity files for bankruptcy, agrees to sell assets

    In an announcement , California-based Sungevity reveals it has commenced voluntary Chapter 11 proceedings in U.S. If approved by the bankruptcy court, Northern Pacific would obtain essentially all of the assets of Sungevity.
  • Crazy Volume Spikes for: Auris Medical Holding AG (NASDAQ:EARS)

    The stock is now moving above its 20-Day Simple Moving Average of -14.13% with the 50-Day Simple Moving Average of -14.13 percent. The consensus recommendation by Thomson Reuters analysts is Buy and their mean rating for the stock is 1.00 on scale of 1-5.
    Buick Enclave Gets New Grille and Curvaceous Headlights

    Buick Enclave Gets New Grille and Curvaceous Headlights

    In another report, the 2018 Buick Enclave is expected to carry the 3.6-liter V-6 for the standard model. With regard to shape, the 2018 Buick Enclave is expected to have some resemblance with its predecessor.
    Kantar: Windows Mobile sales market share drops to 1.3% in the US

    Kantar: Windows Mobile sales market share drops to 1.3% in the US

    With numerous new smartphones announced at MWC not headed to the USA for now, this looks unlikely to change in the near future. Nothing much is changing in the US , where just three brands take home more than four-fifths of all sales.

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.